Protein tyrosine kinases as new potential targets against human schistosomiasis.
In spite of the numerous efforts made to control their transmission, parasite schistosomes still represent a serious public health concern and a major economic problem in many developing countries. Praziquantel (PZQ) is the drug of choice for the treatment of schistosomiasis and the only one that is available for mass chemotherapy. However, its widespread use and its inefficacy on juvenile parasites raise fears that schistosomes will develop drug resistance, and make the development of alternative drugs highly desirable. Protein tyrosine kinases (PTKs) are key molecules that control cell differentiation and proliferation and they already represent important targets for molecular cancer therapy. The recent characterization in Schistosoma mansoni of several cytosolic and receptor PTKs, with properties similar but also divergent from their vertebrate counterparts, opens new perspectives for the development of novel strategies in chemotherapy of schistosomiasis, which could be based on the use of parasite-specific tyrosine phosphorylation inhibitors.
Dissous
Colette
C
Inserm, U 547, Université Lille, France. colette.dissous@pasteur-lille.fr
Ahier
Arnaud
A
Khayath
Naji
N
D000595:Amino Acid Sequence; D000818:Animals; D003593:Cytoplasm / Q000201:enzymology; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism; D008969:Molecular Sequence Data; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000737:chemistry; D012547:Schistosoma / Q000201:enzymology; D012552:Schistosomiasis / Q000201:enzymology* / Q000628:therapy*; D015398:Signal Transduction
D036341:Intercellular Signaling Peptides and Proteins; D011505:Protein-Tyrosine Kinases